COMPARATIVE ANALYSIS OF MEDICINE'S PURCHASSING PRICES OF "ADDITIONAL LIST"(APHP VERSUS FRENCH HOSPITALS FORMELY UNDER OVERALL ALLOCATION)
Author(s)
Doffou E1, Degrassat-Theas A2, Paubel P3
1Teaching Hospital of Yopougon (Côte d'Ivoire), Abidjan, Cote d'Ivoire, 2Assistance publique des hôpitaux de Paris, Paris, France, 3Université Paris sorbonne Cité, Paris, France
OBJECTIVES: The objective of this study was to analyze the purchasing prices of the "additional list" drugs obtained by APHP in comparison to French hospitals formerly under overall allocation (ex-UOA). METHODS: We conduct a retrospective, cross-sectional comparative study over the period 2011-2015. The comparators selected are the ex-UOA hospitals. Annual data on consumption, local and national expenditure are extracted from the databases of the Hospital Information Technology Agency, respectively “ePMSI” and “Scansanté”. Information on the level of “added medical benefit” (AMB), the status of medicines and their molecular nature are obtained from the Thériaque® database, the French public drug database and the French national generic’s register supplemented for therapeutically equivalent by the General Agency of Equipment and Health Products of Paris hospitals (AGEPS). Comparisons are made with the average national purchase prices, excluding AP-HP, and the average AP-HP purchase prices. The robustness of the APHP data is determined by comparison to the declarative data with the data contained in the internal database of AGEPS. Software R is used. RESULTS: Our study covers 1227 references of common unit of dispensing (CUD) (2011-2015). For the majority (46% - 55%) of CUDs, the purchase price declared by the APHP is equal to the average purchase price of the comparator. APHP obtains better purchase prices on a larger number of CUDs (28% -32%) than the comparator (20% -23%). The volume of consumption and the level of ASMR don’t have significant impact on distribution of the price differentials. By contrast, reimbursement price cap (RPC), molecular nature (monoclonal antibodies or human immunoglobulins) and the existence of competition have significant impact on distribution of price differentials. For the most CUDs, APHP's declarative data are different with data contained in the internal database of AGEPS CONCLUSIONS: In general, APHP obtains better purchase prices than ex-UOA hospitals for low-RPC medicines, human immunoglobulins and medicines subject to competition.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PHP13
Topic
Health Policy & Regulatory
Topic Subcategory
Pricing Policy & Schemes
Disease
Multiple Diseases